Jasper Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7552
- Today's High:
- $0.8
- Open Price:
- $0.78
- 52W Low:
- $0.386
- 52W High:
- $3.8
- Prev. Close:
- $0.77
- Volume:
- 328183
Company Statistics
- Market Cap.:
- $127.42 million
- Book Value:
- 0.995
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -37.42%
- Return on Equity TTM:
- -65.58%
Company Profile
Jasper Therapeutics Inc had its IPO on 2021-09-24 under the ticker symbol JSPR.
The company operates in the Healthcare sector and Biotechnology industry. Jasper Therapeutics Inc has a staff strength of 35 employees.
Stock update
Shares of Jasper Therapeutics Inc opened at $0.78 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.76 - $0.8, and closed at $0.76.
This is a -1.91% slip from the previous day's closing price.
A total volume of 328,183 shares were traded at the close of the day’s session.
In the last one week, shares of Jasper Therapeutics Inc have slipped by -34.32%.
Jasper Therapeutics Inc's Key Ratios
Jasper Therapeutics Inc has a market cap of $127.42 million, indicating a price to book ratio of 0.5066 and a price to sales ratio of 0.
In the last 12-months Jasper Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-57139000. The EBITDA ratio measures Jasper Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Jasper Therapeutics Inc’s operating margin was 0% while its return on assets stood at -37.42% with a return of equity of -65.58%.
In Q2, Jasper Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Jasper Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.98 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Jasper Therapeutics Inc’s profitability.
Jasper Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4439. Its price to sales ratio in the trailing 12-months stood at 0.
Jasper Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $124.17 million
- Total Liabilities
- $8.97 million
- Operating Cash Flow
- $-11000.00
- Capital Expenditure
- $11000
- Dividend Payout Ratio
- 0%
Jasper Therapeutics Inc ended 2024 with $124.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $124.17 million while shareholder equity stood at $110.21 million.
Jasper Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.97 million in other current liabilities, 11000.00 in common stock, $-135475000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $115.81 million and cash and short-term investments were $115.81 million. The company’s total short-term debt was $917,000 while long-term debt stood at $0.
Jasper Therapeutics Inc’s total current assets stands at $118.57 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $330000.00 compared to accounts payable of $1.58 million and inventory worth $1.77 million.
In 2024, Jasper Therapeutics Inc's operating cash flow was $-11000.00 while its capital expenditure stood at $11000.
Comparatively, Jasper Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.76
- 52-Week High
- $3.8
- 52-Week Low
- $0.386
- Analyst Target Price
- $6.25
Jasper Therapeutics Inc stock is currently trading at $0.76 per share. It touched a 52-week high of $3.8 and a 52-week low of $3.8. Analysts tracking the stock have a 12-month average target price of $6.25.
Its 50-day moving average was $1.34 and 200-day moving average was $1.44 The short ratio stood at 4.65 indicating a short percent outstanding of 0%.
Around 791% of the company’s stock are held by insiders while 8768.1% are held by institutions.
Frequently Asked Questions About Jasper Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.